An anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Choice of linker.
The anti-CD33 antibody, P67.6, has been chosen to target the potently cytotoxic calicheamicin antitumor antibiotics to acute myeloid leukemia (AML) due to the presence of CD33 on >80% of patient samples and its lack of expression outside the myeloid cell lineages, especially its lack of expression on pluripotent stem cells. Previous calicheamicin conjugates relied on the attachment of a hydrazide derivative to the oxidized carbohydrates that occur naturally on antibodies. This results in a "carbohydrate conjugate" capable of releasing active drug by hydrolysis of a hydrazone bond in the lysozomes where the pH is low. Conjugates have now been made that are formed by reacting a calicheamicin derivative containing an activated ester with the lysines of antibodies. This results in an "amide conjugate" that is stable to hydrolysis, leaving the disulfide that is present in all calicheamicin conjugates as the likely site of drug release from the conjugate. In this article, these two classes of calicheamicin-antibody conjugates are compared for potential use in AML with the anti-CD33 antibody P67.6. Conjugates of P67.6 are shown to require the site of hydrolytic release afforded by the carbohydrate conjugates in order to retain good potency and selectivity in vitro, in vivo, and ex vivo. The P67.6 carbohydrate conjugate of calicheamicin is selectively cytotoxic at <0.006 ng/mL of calicheamicin equivalents (cal equiv) toward HL-60 promyelocytic leukemia cells in tissue culture. Long-term, tumor-free survivors are seen in xenograft models when mice bearing HL-60 subcutaneous tumors are treated with the P67.6 carbohydrate conjugate at a dose of 300 microg/kg cal equiv given three times. This conjugate also selectively inhibits the formation of colonies from AML marrow samples at 2 ng/mL cal equiv. The P67.6 carbohydrate conjugate of calicheamicin therefore appears to have promise as an antibody-targeted chemotherapeutic agent for CD33-positive diseases such as AML.
Hamann
Philip R
PR
Wyeth-Ayerst Research, 401 North Middletown Road, Pearl River, New York 10965, USA. hamannp@war.wyeth.com
Hinman
Lois M
LM
Beyer
Carl F
CF
Lindh
Delores
D
Upeslacis
Janis
J
Flowers
David A
DA
Bernstein
Irwin
I
D000208:Acute Disease; D000617:Aminoglycosides; D000818:Animals; D000900:Anti-Bacterial Agents / Q000737:chemistry* / Q000627:therapeutic use*; D000903:Antibiotics, Antineoplastic / Q000737:chemistry* / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000737:chemistry* / Q000627:therapeutic use*; D015703:Antigens, CD / Q000276:immunology*; D015214:Antigens, Differentiation, Myelomonocytic / Q000276:immunology*; D018922:HL-60 Cells; D006801:Humans; D007120:Immunochemistry; D000922:Immunotoxins / Q000737:chemistry* / Q000627:therapeutic use*; D007951:Leukemia, Myeloid / Q000188:drug therapy*; D009682:Magnetic Resonance Spectroscopy; D051379:Mice; D008819:Mice, Nude; D063268:Sialic Acid Binding Ig-like Lectin 3; D013055:Spectrophotometry, Infrared; D013056:Spectrophotometry, Ultraviolet
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D000903:Antibiotics, Antineoplastic; D000911:Antibodies, Monoclonal; D015703:Antigens, CD; D015214:Antigens, Differentiation, Myelomonocytic; C571163:CD33 protein, human; C571165:Cd33 protein, mouse; D000922:Immunotoxins; D063268:Sialic Acid Binding Ig-like Lectin 3